Abstract:

BACKGROUND: Basic and clinical studies have shown that many factors are involved in stent restenosis. In-stent restenosis is correlated with stent, and smoking, diabetes and unstable angina are also important predictors. Glycated hemoglobin is the monitor index of diabetes and biomarker of cardiovascular disease.
OBJECTIVE: To evaluate coronary stent plant in-stent restenosis after implantation, and the relationship between glycated hemoglobin.
METHODS: A total of 36 patients with successful coronary stenting received atherosclerotic heart disease, were divided into 3 groups according to the level of glycated hemoglobin and fasting blood glucose: normal glycosylated hemoglobin and fasting blood sugar group (n = 11), normal glycosylated hemoglobin and elevated fasting glucose group (n = 15), increased glycosylated hemoglobin and fasting blood glucose group (n = 10). Because of chest pain after stent implantation in patients with recurrent or routine follow-up coronary angiography, the original target lesion ≥ 50% luminal diameter stenosis was in-stent restenosis in the control of glycosylated hemoglobin on coronary artery restenosis.
RESULTS AND CONCLUSION: Of 36 patients, 7 cases had coronary artery restenosis, accounting for 19%, including 1 in normal glycosylated hemoglobin and fasting blood sugar group, 2 in normal glycosylated hemoglobin and elevated fasting glucose group and 4 in increased glycosylated hemoglobin and fasting blood glucose group. Glycosylated hemoglobin and fasting plasma glucose were greater in increased glycosylated hemoglobin and fasting blood glucose group compared with the other two groups (P < 0.05). The regression analysis showed that glycosylated hemoglobin is one important factor for restenosis following a coronary stent. Glycosylated hemoglobin measurement can further  assess the coronary risk of restenosis after stent implantation.